Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
…, K Vernovsky, EJ Mark, M Lanuti, AJ Iafrate… - Science translational …, 2011 - science.org
Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
…, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate… - Jama, 2014 - jamanetwork.com
Importance Targeting oncogenic drivers (genomic alterations critical to cancer development
and maintenance) has transformed the care of patients with lung adenocarcinomas. The …
and maintenance) has transformed the care of patients with lung adenocarcinomas. The …
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
…, JC Saeh, K Crosby, LV Sequist, AJ Iafrate… - Science translational …, 2012 - science.org
Most anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLCs) are
highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However, patients …
highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However, patients …
[HTML][HTML] Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
…, GI Shapiro, JW Clark, AJ Iafrate - … England Journal of …, 2010 - Mass Medical Soc
Background Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK)
are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such …
are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such …
[PDF][PDF] COVID-19-neutralizing antibodies predict disease severity and survival
…, JK Lennerz, D Lingwood, AG Schmidt, AJ Iafrate… - Cell, 2021 - cell.com
Coronavirus disease 2019 (COVID-19) exhibits variable symptom severity ranging from
asymptomatic to life-threatening, yet the relationship between severity and the humoral immune …
asymptomatic to life-threatening, yet the relationship between severity and the humoral immune …
[PDF][PDF] mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
…, DJ Gregory, MC Poznansky, AG Schmidt, AJ Iafrate… - Cell, 2022 - cell.com
Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529)
harboring up to 36 mutations in spike protein, the target of neutralizing antibodies…
harboring up to 36 mutations in spike protein, the target of neutralizing antibodies…
[HTML][HTML] Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
…, MC Poznansky, A Sigal, AG Schmidt, AJ Iafrate… - Cell, 2021 - cell.com
Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However,
ongoing surveillance has revealed the emergence of variants harboring mutations in …
ongoing surveillance has revealed the emergence of variants harboring mutations in …
Detection of large-scale variation in the human genome
AJ Iafrate, L Feuk, MN Rivera, ML Listewnik… - Nature …, 2004 - nature.com
We identified 255 loci across the human genome that contain genomic imbalances among
unrelated individuals. Twenty-four variants are present in > 10% of the individuals that we …
unrelated individuals. Twenty-four variants are present in > 10% of the individuals that we …
[HTML][HTML] Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK
…, EL Kwak, TJ Lynch, AJ Iafrate - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose The EML4-ALK fusion oncogene represents a novel molecular target in a small
subset of non–small-cell lung cancers (NSCLC). To aid in identification and treatment of these …
subset of non–small-cell lung cancers (NSCLC). To aid in identification and treatment of these …
[HTML][HTML] Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
…, E Inserra, S Diederichs, AJ Iafrate… - … England Journal of …, 2008 - Mass Medical Soc
Background The use of tyrosine kinase inhibitors to target the epidermal growth factor
receptor gene (EGFR) in patients with non–small-cell lung cancer is effective but limited by the …
receptor gene (EGFR) in patients with non–small-cell lung cancer is effective but limited by the …